Phaseline

Companies › Jade Biosciences

Jade Biosciences: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 3 Phase 1, 1 Phase 3, 1 Phase 2; Genitourinary, Other, Immunology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JADE101–Phase 3IgA Nephropathy (IgAN); IgA Nephropathy; Healthy Volunteers; Healthy Volunteers (HV)May 2027
JADE201–Phase 1Rhematoid ArthritisOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07059312JADE101Phase 1Healthy VolunteersOtherOct 2026
NCT07525947JADE101Phase 1Healthy Volunteers (HV)OtherMay 2027
NCT07533955JADE201Phase 1Rhematoid ArthritisImmunologyOct 2027
NCT07541287JADE101Phase 2IgA NephropathyGenitourinaryJan 2029
NCT07902817JADE101Phase 3IgA Nephropathy (IgAN)GenitourinaryJun 2029

From the company's SEC filings

Cash and short-term investments of $461m on 2026-06-30; operating cash outflow about $137m a year; runway about 40 months at that burn, to Nov 2029; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 13 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Akebia Therapeutics Sagimet Biosciences Kymera Therapeutics Oruka Therapeutics Abivax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.